Myopathy is a Risk Factor for Poor Prognosis of Patients wit
Now open: Certificate Course in Management of Covid-19 by Govt. Of Gujarat and PlexusMDKnow more...Now open: Certificate Course in Management of Covid-19 by Govt. Of Gujarat and PlexusMDKnow more...
To compare clinical characteristics and identify long-term outcomes of patients with systemic sclerosis (SSc) with and without muscle involvement a study was conducted.

Researchers retrospectively investigated the medical records, laboratory results, and computed tomography images of 204 consecutive SSc patients. Kaplan–Meier analysis was performed to determine survival rates. Patients were allocated into groups with and without myopathy.

The prevalence of myopathy was 21.6%. The myopathy group was more likely to develop diffuse cutaneous involvement (90.9% vs 56%), interstitial lung disease (90% vs 56%), digestive system involvement (56.7% vs 29.3%), pulmonary hypertension (29.5% vs 10.5%), and pericardial effusion (25% vs. 10%). Patients with myopathy had lower single-breath diffusing capacity of the lung for carbon oxide (46.5 ± 11.1 vs 57.1 ± 13.4).
Further, the myopathy group has similar results in interstitial lung disease associated higher resolution computed tomography score (186.8 ± 64.5 vs 152.3 ± 45.5), Valentini score for disease activity (3.4 ± 0.9 vs 2.0 ± 0.9) and modified Rodnan total skin score (19.4 ± 6.1 vs 15.1 ± 7.7), compared with non-myopathy group. Survival analysis revealed decreased overall survival rate of the myopathy group (P = .028).

SSc Patients with myopathy had more severe clinical manifestations and higher disease activity compared with those without, which affected survival rates and indicated worse prognosis.

Source: https://journals.lww.com/md-journal/subjects/Rheumatology/Fulltext/2020/08140/Myopathy_is_a_Risk_Factor_for_Poor_Prognosis_of.92.aspx
Like
Comment
Share